IPHYF (Innate Pharma) Interest Expense: $-0.51 Mil (TTM As of Dec. 2025)

What is Innate Pharma Interest Expense?

Innate Pharma IPHYF 29 Interest Expense is $-0.51 Mil as of Dec. 2025. GuruFocus rates IPHYF with a GF Score™ of 29/100 and a GF Value™ of $0.14 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Innate Pharma's interest expense for the six months ended in Dec. 2025 was $ -0.25 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.51 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Innate Pharma's Operating Income for the six months ended in Dec. 2025 was $ -32.79 Mil. Innate Pharma's Interest Expense for the six months ended in Dec. 2025 was $ -0.25 Mil. Innate Pharma did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Innate Pharma (OTCPK:IPHYF) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Innate Pharma's Interest Expense for the six months ended in Dec. 2025 was $-0.25 Mil. Its Operating Income for the six months ended in Dec. 2025 was $-32.79 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was $16.13 Mil.

Innate Pharma's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Innate Pharma did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Innate Pharma Interest Expense Historical Data

* Premium members only.

The historical data trend for Innate Pharma's Interest Expense can be seen below:

Innate Pharma Interest Expense Chart

Innate Pharma Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Interest Expense

Get a 7-Day Free Trial

-0.35

-0.31

-0.70

-0.59

-0.52

Innate Pharma Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Interest Expense	Get a 7-Day Free Trial															0.36	-0.32	-0.28	-0.26	-0.25

29GF Score

Innate Pharma SA IPHYF

Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Innate Pharma Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.51 Mil.

Frequently Asked Questions Learn more about Interest Expense →

What does a Interest Expense of $-0.51 Mil mean?

Innate Pharma (IPHYF) has a Interest Expense of $-0.51 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Innate Pharma and its competitors.

Is Innate Pharma's Interest Expense too high?

Innate Pharma's current Interest Expense is $-0.51 Mil. Overall, Innate Pharma has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Innate Pharma's Interest Expense compare to VRTX and REGN?

Innate Pharma's Interest Expense of $-0.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Interest Expense for a Biotechnology company?

A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Interest Expense mean?

A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Innate Pharma and its competitors. Innate Pharma's current Interest Expense is $-0.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Innate Pharma stock overvalued right now?

Based on GuruFocus' analysis, Innate Pharma (IPHYF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.14, compared to a current price of $1.65 — trading 1078.6% above its estimated fair value. The current Interest Expense is $-0.51 Mil. Innate Pharma's overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Interest Expense calculated?

Interest Expense is calculated from a company's financial statements. For Innate Pharma (IPHYF), the current Interest Expense is $-0.51 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Innate Pharma (IPHYF) Overvalued in 2026?

Based on GuruFocus' analysis, Innate Pharma stock appears to be overvalued. The current stock price of $1.65 is trading 1078.6% above its estimated GF Value™ of $0.14. GuruFocus considers Innate Pharma to be Significantly Overvalued.

Key valuation signals for IPHYF:

Interest Expense: $-0.51 Mil
GF Value™: $0.14 vs. price of $1.65 (1078.6% above fair value)
GF Score™: 29/100 with 7 warning signs

No single metric tells the full story. See the IPHYF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Innate Pharma Business Description

Industry Healthcare Biotechnology

Comparable Companies XPAR:ALSEN XPAR:ALVIO XPAR:TNG XPAR:ABNX XPAR:ADOC XPAR:OSE XPAR:ALGAE XPAR:ALCLS XPAR:MAAT XPAR:ALTHX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges IPHA:USA 0EVI:UK IPH:France IDD:Germany

Address 117, Avenue de Luminy, Marseille, FRA, 13009

Website https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

29GF Score

Get the complete analysis for IPHYF

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.65

Price

$0.14

GF Value

View IPHYF Analysis

See Interest Expense data for all stocks →